Denali Therapeutics (DNLI) News Today $20.75 -0.84 (-3.87%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$20.77 +0.02 (+0.08%) As of 02/21/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Empowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Empowered Funds LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 18,587 shares of the company's stock, valueFebruary 21 at 3:05 AM | marketbeat.comDenali Therapeutics (DNLI) to Release Quarterly Earnings on TuesdayDenali Therapeutics (NASDAQ:DNLI) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comBaillie Gifford & Co. Cuts Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Baillie Gifford & Co. trimmed its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 7.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,313,931 shares of the company's stock afterFebruary 17, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Coverage Initiated at Deutsche Bank AktiengesellschaftFebruary 14, 2025 | americanbankingnews.comDeutsche Bank Initiates Coverage of Denali Therapeutics (DNLI) with Buy RecommendationFebruary 12, 2025 | msn.comDeutsche Bank sets $31 target for Denali Therapeutics stockFebruary 11, 2025 | msn.comDenali Therapeutics initiated with a Buy at Deutsche BankFebruary 11, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Shares Gap Up - Time to Buy?Denali Therapeutics (NASDAQ:DNLI) Shares Gap Up - Here's WhyFebruary 11, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday. They set a "buy" rating and a $31.00 price objective on the stock.February 11, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.9% - Here's What HappenedDenali Therapeutics (NASDAQ:DNLI) Trading Down 4.9% - Time to Sell?February 10, 2025 | marketbeat.comStifel maintains Buy on Denali Therapeutics, $37 targetFebruary 10, 2025 | msn.comDenali Therapeutics (DNLI) Gets a Buy from Stifel NicolausFebruary 10, 2025 | markets.businessinsider.comabrdn plc Has $8.20 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)abrdn plc increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 10.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 402,282 shares of the company's stock afterFebruary 9, 2025 | marketbeat.comDenali Therapeutics announces primary analysis of Phase 1/2 study in MPS IIFebruary 6, 2025 | markets.businessinsider.comDenali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp AlfaFebruary 6, 2025 | globenewswire.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of "Moderate Buy" from BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen brokerages that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and oneFebruary 4, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Sees Large Increase in Short InterestDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 7,840,000 shares, an increase of 5.1% from the December 31st total of 7,460,000 shares. Currently, 6.3% of the shares of the company are short sold. Based on an average trading volume of 868,500 shares, the short-interest ratio is currently 9.0 days.February 3, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.2% - Should You Sell?Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.2% - What's Next?February 3, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic View of DNLI FY2025 EarningsDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Denali Therapeutics in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($3.45) peJanuary 31, 2025 | marketbeat.comWhat is Zacks Research's Estimate for DNLI FY2024 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Zacks Research dropped their FY2024 earnings estimates for shares of Denali Therapeutics in a research note issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty now expects that the company will post earninJanuary 31, 2025 | marketbeat.comThe Goldman Sachs Group Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $40.00The Goldman Sachs Group dropped their target price on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a report on Tuesday.January 28, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Trading Down 4.3% - Here's What HappenedDenali Therapeutics (NASDAQ:DNLI) Shares Down 4.3% - What's Next?January 24, 2025 | marketbeat.comResearch Analysts Issue Forecasts for DNLI FY2025 EarningsDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Denali Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($2.86)January 22, 2025 | marketbeat.comDenali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy RatingJanuary 21, 2025 | markets.businessinsider.comDenali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Up 5.1% in DecemberDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 7,840,000 shares, a growth of 5.1% from the December 15th total of 7,460,000 shares. Based on an average trading volume of 868,500 shares, the days-to-cover ratio is currently 9.0 days. Currently, 6.3% of the company's shares are sold short.January 20, 2025 | marketbeat.comWhy Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside PotentialJanuary 17, 2025 | msn.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Increased by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 235,386 shares of the company's stock after buying an additionaJanuary 16, 2025 | marketbeat.comWhy Is Denali Therapeutics Stock Trading Higher On Wednesday?January 15, 2025 | benzinga.comDenali Therapeutics (NASDAQ:DNLI) Trading 9.8% Higher - Time to Buy?Denali Therapeutics (NASDAQ:DNLI) Trading 9.8% Higher - Should You Buy?January 15, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Receives Outperform Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of Denali Therapeutics in a research note on Wednesday.January 15, 2025 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)January 15, 2025 | markets.businessinsider.comDenali Therapeutics sees cash runway into 2028January 13, 2025 | msn.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendJanuary 10, 2025 | marketbeat.comDenali: Despite ALS Primary Endpoint Failure, Possible Path Forward RemainsJanuary 9, 2025 | seekingalpha.comWhy biotech startup Tenvie sees promise in drugs from founders' old companyJanuary 9, 2025 | bizjournals.comWhat is HC Wainwright's Forecast for DNLI FY2026 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($January 9, 2025 | marketbeat.comSteve E. Krognes Sells 3,339 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockJanuary 9, 2025 | insidertrades.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,339 Shares of StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Steve E. Krognes sold 3,339 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the sale, the director now directly owns 25,757 shares of the company's stock, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.January 8, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 SharesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares in the company, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.January 8, 2025 | marketbeat.comRyan J. Watts Sells 29,266 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company's stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.January 8, 2025 | marketbeat.comDenali Therapeutics announces U.S. FDA BTD granted for tividenofuspJanuary 8, 2025 | markets.businessinsider.comDenali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)January 8, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Trading Up 3.1% - What's Next?Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 3.1% - Here's WhyJanuary 8, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for DNLI FY2028 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will post eJanuary 8, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Upgraded to "Strong-Buy" at Baird R WBaird R W upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Tuesday.January 8, 2025 | marketbeat.comDenali Therapeutics price target lowered to $32 from $35 at BTIGJanuary 8, 2025 | markets.businessinsider.comBofA trims Denali Therapeutics price target to $30, says weakness an opportunityJanuary 7, 2025 | markets.businessinsider.comDenali Therapeutics (DNLI) Gets a Buy from J.P. MorganJanuary 7, 2025 | markets.businessinsider.comBaird Initiates Coverage of Denali Therapeutics (DNLI) with Outperform RecommendationJanuary 7, 2025 | msn.comJPMorgan Chase & Co. Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $24.00JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a research note on Tuesday.January 7, 2025 | marketbeat.com Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Media Mentions By Week DNLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNLI News Sentiment▼0.650.60▲Average Medical News Sentiment DNLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNLI Articles This Week▼35▲DNLI Articles Average Week Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Today Vaxcyte News Today Sarepta Therapeutics News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Legend Biotech News Today BridgeBio Pharma News Today Axsome Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNLI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts